Stephen Pentoney has been named vice president of array biochemistry at Illumina, the firm said this week. He will be responsible for leading Illumina's assay and application development efforts.
Prior to joining Illumina, Pentoney served as director of technology management for Beckman Coulter’s Molecular Diagnostics Business Center. From 1999 to 2007, he was the director of advanced systems chemistry for Beckman Coulter's Advanced Technology Center.
Pentoney holds a BS in chemistry from California State University and a PhD in analytical chemistry from the University of California. He completed his postdoctoral research in laser-based chemical analysis at Stanford University.
Illumina said it granted an option to purchase 56,000 shares of its common stock to Pentoney as part of his inducement to join the company. The option has an exercise price equal to the closing fair market value of Illumina's common stock on the grant date, a 10-year term and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter. The closing price for shares of Illumina’s stock was $84.04 on July 21, the grant date.
GE Healthcare CEO Joseph Hogan has left the company to take a position as CEO of the power and automation company ABB. GE has named John Dineen, who until now was CEO of GE Transportation, to fill Hogan’s spot.
Alan Fletcher has joined PerkinElmer as vice president of business development for the company’s Life and Analytical Sciences business. Fletcher most recently held multiple positions at GE Healthcare and before that he was involved in biotechnology, R&D, and technology transfer for other Fortune 500 companies. He has a doctorate in biochemical pharmacology from the University of London.
William Sullivan has taken on the role of senior vice president of diagnostic operations at HistoRx. In the newly created job, Sullivan will be responsible for expanding the company’s diagnostics development and manufacturing. Sullivan was VP of corporate development for Vermillion (previously Ciphergen), and he was VP of operations at Nichols Institute Diagnostics.